⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23595697 | 1.00 | — | — | |
| SCHEMBL3052073 | 0.86 | KDM1A (0.47) | — | |
| SCHEMBL23595690 | 0.80 | KDM1A (0.45) | — | |
| SCHEMBL23595661 | 0.80 | KDM1A (0.45) | — | |
| SCHEMBL8777356 | 0.79 | OPRL1 (0.44) | — | |
| SCHEMBL2873982 | 0.78 | KCNN4 (0.38) | — | |
| SCHEMBL12976851 | 0.78 | KCNN4 (0.38) | — | |
| SCHEMBL6356771 | 0.78 | KDM1A (0.43) | — | |
| SCHEMBL6356774 | 0.78 | KDM1A (0.43) | — | |
| SCHEMBL6356769 | 0.78 | KDM1A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |